explore -WSS

explore

author：leisure time 2025-09-29 22:48:48 - browse：619

Novo Nordisk headquarters -- health coverage from STAT — Novo Nordisk's headquarters, outside Copenhagen, Denmark. LISELOTTE SABROE/Scanpix/AFP via Getty Images

Novo Nordisk is pausing ads for its obesity drug Wegovy as it struggles to keep up with surging demand, the latest hurdle in its rollout of the weight loss drug.

“To avoid stimulating further demand for this medicine, we’re pausing some key Wegovy promotional efforts,” the Danish drugmaker said in an emailed statement. “We are pausing all local television advertising and postponing planned national television advertising for Wegovy. We are also assessing our promotional efforts to healthcare professionals and adjusting accordingly.” The news was earlier reported by Endpoints.

Wegovy, which contains the active ingredient semaglutide, has become immensely popular for its effectiveness in helping people lose weight and is helping usher in what many see as a sea change in obesity treatment. Its sister drug for diabetes, Ozempic, has also been in demand for a similar effect on weight loss.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Indian pharmaceutical industry in denial over drug

WSS

Stanford president's case begs question: Who takes blame?

Ending racial health disparities hinges on penalties, political will

Vivek Ramaswamy made waves in the debate, much as in biotech

Stanford president faces new allegations over 1999 paper

DeSantis wants to import drugs. Biden’s FDA blasted his plan

People can get long Covid without testing positive for virus: Study

Wikipedia

explore

knowledge

Walensky prepares to leave CDC — and Congress — behind

7 more heat

Medicare details structure of new drug price negotiation program

How the first Native Hawaiian psychiatrist helped diversify medicine

In age of alternative facts, a scholarly course on calling out crap

DeSantis wants to import drugs. Biden’s FDA blasted his plan

United colonoscopy coverage change 'may cost lives,' doctors say

Study identifies new proteins linked to dementia risk 25 years later

Alkermes shareholders re

Wife of Gilgo Beach murder suspect files for divorce, court filing shows

hotspot

Intellia plays down concerns on accidental germline transmission

Meadows told special counsel he could not recall Trump ever declassifying Mar

Health officials lay out plans to cope with respiratory virus season

Vivek Ramaswamy made waves in the debate, much as in biotech

Study: Spinal cord stimulation helps patients with paralysis walk again

7 more heat

explore

hotspot

entertainment

explore